Skip to main content

Worg secures financing of 130 million Swiss francs

| News

Worg secures financing of 130 million Swiss francs


The Chinese biopharmaceutical firm Worg Pharma, whose European headquarters are located in the Basel Area, has secured gross proceeds equivalent to 130 million Swiss francs as part of a Series C financing round. The funds are set to be put towards research and development activities, growth plans, new projects and personnel.


Worg Pharma has raised 1.1 billion renminbi as part of a Series C financing round, which is the equivalent of 130 million Swiss francs. Founded in 2018, the biopharmaceutical company is headquartered in the Chinese city of Hangzhou, with European headquarters at the Switzerland Innovation Park Basel Area since 2021. Basel Area Business & Innovation, the investment and innovation promotion agency, supported Worg in establishing a presence in the Basel Area with consulting services and legal help, as well as by assisting the search for premises.

The company specializes in the development of innovative therapies to treat allergies and autoimmune diseases. According to a press release, DeTong Capital, Paramount Capital, the YSIM Fund from Germany, SeeSu Capital, the Kequan Fund, Kangjun Capital, an unnamed “well-known European financial institution” participated in the financing round alongside existing investors. The company is led by a management team from China, the USA and Europe.

Development at a faster speed

“With the success of the Series C financing round, the company will actively promote the development of additional product pipelines at a faster speed and make every effort to fully accelerate the integration of clinical and commercialization processes”, comments CEO and founder Dr. Xu Aiwu. In specific terms, the fresh capital is to be put towards the global development and commercial expansion of the existing product pipeline. In addition, the investment will be used to build the independent research and development platform as well as to launch new projects and expand the international team.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.